Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

• Contrast-induced nephropathy (CIN) is the third most common cause of hospital acquired acute kidney injury, accounting for 10% of all cases.

• The pathophysiology of CIN is unclear. Possible mechanisms involve

1. Renal tubular injury by oxygen free radicals

2. Reducing renal blood flow which leads to acute tubular necrosis. Since N-acetylcysteine is an antioxidant as well as a vasodilator, it may work in two distinct ways, by preventing reduction in renal blood flow or contrast-induced oxidative damage.

• The purpose of this study is to evaluate the efficacy of N-acetylcysteine compared to placebo for the contrast-induced nephropathy prevention.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

Patients who have all of the following criteria:

• Aged older than 18 years old

• A history of diabetes mellitus for at least one year

• chronic kidney disease, defined as serum creatinine concentration >=1.5mg/dL for men and >=1.4mg/dL for women.

Exclusion Criteria:

• Acute coronary syndrome requiring primary or rescue coronary intervention within less than 12h

• Cardiogenic shock

• Current peritoneal or hemo-dialysis

• A known allergy to NAC